FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893103482> ?p ?o ?g. }

• W2893103482 endingPage "e646" @default.
• W2893103482 startingPage "e638" @default.
• W2893103482 abstract "Background Implementation of ultrasensitive HIV drug resistance tests for routine clinical use is hampered by uncertainty about the clinical relevance of drug-resistant minority variants. We assessed different detection thresholds for pretreatment drug resistance to predict an increased risk of virological failure. Methods We did a case-control study nested within a prospective multicountry cohort. Our study included patients from 12 clinical sites in Kenya, Nigeria, South Africa, Uganda, and Zambia. We defined cases as patients with virological failure (ie, those who had either viral load ≥400 copies per mL at 12 months or had switched to second-line antiretroviral therapy [ART] as a result of virological failure before 12 months) and controls as those with viral suppression (viral load <400 copies per mL at 12 months) on first-line non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. We assessed pretreatment drug resistance with Illumina MiSeq next-generation sequencing, using the International Antiviral Society (IAS)-USA mutation list or the Stanford HIV Drug Resistance Database (HIVDB) genotypic sensitivity score. We calculated diagnostic accuracy measures and assessed the odds of virological failure using conditional logistic regression for 1%, 5%, and 10% pretreatment drug resistance detection thresholds, compared with the conventional 20% or more used in Sanger-based sequencing. Findings Paired viral load results before ART and at month 12 of follow-up were available from 1896 participants. We identified 178 patients with virological failure and selected 338 matched controls. We excluded 117 patients from pretreatment drug resistance analysis; therefore, 152 cases of virological failure and 247 controls were included in the final analysis. With the IAS-USA mutation list, at a detection threshold of 20% or more in patients with pretreatment drug resistance, the adjusted odds ratio (OR) for virological failure was 9·2 (95% CI 4·2–20·1) compared with those without pretreatment drug resistance. Lowering the threshold resulted in adjusted ORs of virological failure of 6·8 (95% CI 3·3–13·9) at the 10% threshold, 7·6 (3·4–17·1) at the 5% threshold, and 4·5 (2·0–10·2) at the 1% threshold. Lowering the detection threshold from 20% improved the sensitivity (ie, ability to identify cases) from 12% (n=18) to 13% (n=19) at detection threshold 10%, to 15% (n=23) at detection threshold 5%, and to 17% (n=26) at detection threshold 1%, but caused a slight reduction in specificity (ie, ability to identify controls) from 98% (n=241) to 96% (n=238) at the 10% threshold, 96% (n=236) at the 5% threshold, and a larger reduction to 92% (n=227) at the 1% threshold. Diagnostic ORs were 5·4 (95% CI 2·1–13·9) at the 20% threshold, 3·8 (1·7–8·6) at the 10% threshold, 3·8 (1·8–8·1) at the 5% threshold, and 2·3 (1·2–4·2) at the 1% threshold. Use of the Stanford HIVDB genotypic sensitivity scores yielded similar ORs for virological failure, sensitivities, specificities, and diagnostic ORs. Interpretation Ultrasensitive resistance testing for pretreatment drug resistance improved identification of people at risk of virological failure; however, this came with a reduction in our ability to identify people with viral suppression, especially at very low thresholds. Further modelling is needed to estimate the optimal trade-off for the 5% and 20% thresholds, balancing improved case finding against unnecessary regimen switching. Funding The Netherlands Ministry of Foreign Affairs, IrsiCaixa, and European Union. Implementation of ultrasensitive HIV drug resistance tests for routine clinical use is hampered by uncertainty about the clinical relevance of drug-resistant minority variants. We assessed different detection thresholds for pretreatment drug resistance to predict an increased risk of virological failure. We did a case-control study nested within a prospective multicountry cohort. Our study included patients from 12 clinical sites in Kenya, Nigeria, South Africa, Uganda, and Zambia. We defined cases as patients with virological failure (ie, those who had either viral load ≥400 copies per mL at 12 months or had switched to second-line antiretroviral therapy [ART] as a result of virological failure before 12 months) and controls as those with viral suppression (viral load <400 copies per mL at 12 months) on first-line non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. We assessed pretreatment drug resistance with Illumina MiSeq next-generation sequencing, using the International Antiviral Society (IAS)-USA mutation list or the Stanford HIV Drug Resistance Database (HIVDB) genotypic sensitivity score. We calculated diagnostic accuracy measures and assessed the odds of virological failure using conditional logistic regression for 1%, 5%, and 10% pretreatment drug resistance detection thresholds, compared with the conventional 20% or more used in Sanger-based sequencing. Paired viral load results before ART and at month 12 of follow-up were available from 1896 participants. We identified 178 patients with virological failure and selected 338 matched controls. We excluded 117 patients from pretreatment drug resistance analysis; therefore, 152 cases of virological failure and 247 controls were included in the final analysis. With the IAS-USA mutation list, at a detection threshold of 20% or more in patients with pretreatment drug resistance, the adjusted odds ratio (OR) for virological failure was 9·2 (95% CI 4·2–20·1) compared with those without pretreatment drug resistance. Lowering the threshold resulted in adjusted ORs of virological failure of 6·8 (95% CI 3·3–13·9) at the 10% threshold, 7·6 (3·4–17·1) at the 5% threshold, and 4·5 (2·0–10·2) at the 1% threshold. Lowering the detection threshold from 20% improved the sensitivity (ie, ability to identify cases) from 12% (n=18) to 13% (n=19) at detection threshold 10%, to 15% (n=23) at detection threshold 5%, and to 17% (n=26) at detection threshold 1%, but caused a slight reduction in specificity (ie, ability to identify controls) from 98% (n=241) to 96% (n=238) at the 10% threshold, 96% (n=236) at the 5% threshold, and a larger reduction to 92% (n=227) at the 1% threshold. Diagnostic ORs were 5·4 (95% CI 2·1–13·9) at the 20% threshold, 3·8 (1·7–8·6) at the 10% threshold, 3·8 (1·8–8·1) at the 5% threshold, and 2·3 (1·2–4·2) at the 1% threshold. Use of the Stanford HIVDB genotypic sensitivity scores yielded similar ORs for virological failure, sensitivities, specificities, and diagnostic ORs. Ultrasensitive resistance testing for pretreatment drug resistance improved identification of people at risk of virological failure; however, this came with a reduction in our ability to identify people with viral suppression, especially at very low thresholds. Further modelling is needed to estimate the optimal trade-off for the 5% and 20% thresholds, balancing improved case finding against unnecessary regimen switching." @default.
• W2893103482 created "2018-10-05" @default.
• W2893103482 creator A5001181968 @default.
• W2893103482 creator A5003302321 @default.
• W2893103482 creator A5006363203 @default.
• W2893103482 creator A5006929815 @default.
• W2893103482 creator A5009104141 @default.
• W2893103482 creator A5009248465 @default.
• W2893103482 creator A5010065694 @default.
• W2893103482 creator A5011644912 @default.
• W2893103482 creator A5017678982 @default.
• W2893103482 creator A5018761768 @default.
• W2893103482 creator A5019711611 @default.
• W2893103482 creator A5020544537 @default.
• W2893103482 creator A5021025618 @default.
• W2893103482 creator A5021736604 @default.
• W2893103482 creator A5021757711 @default.
• W2893103482 creator A5024574454 @default.
• W2893103482 creator A5028076370 @default.
• W2893103482 creator A5028130303 @default.
• W2893103482 creator A5028425257 @default.
• W2893103482 creator A5029504632 @default.
• W2893103482 creator A5031077871 @default.
• W2893103482 creator A5036271514 @default.
• W2893103482 creator A5041228589 @default.
• W2893103482 creator A5041294073 @default.
• W2893103482 creator A5041686074 @default.
• W2893103482 creator A5044667291 @default.
• W2893103482 creator A5046062050 @default.
• W2893103482 creator A5051991963 @default.
• W2893103482 creator A5053442063 @default.
• W2893103482 creator A5054060411 @default.
• W2893103482 creator A5057049716 @default.
• W2893103482 creator A5058207584 @default.
• W2893103482 creator A5061752010 @default.
• W2893103482 creator A5062236640 @default.
• W2893103482 creator A5062602190 @default.
• W2893103482 creator A5065647297 @default.
• W2893103482 creator A5070196758 @default.
• W2893103482 creator A5070322756 @default.
• W2893103482 creator A5072858571 @default.
• W2893103482 creator A5072946962 @default.
• W2893103482 creator A5074983048 @default.
• W2893103482 creator A5077325229 @default.
• W2893103482 creator A5080859236 @default.
• W2893103482 creator A5082893003 @default.
• W2893103482 creator A5084363644 @default.
• W2893103482 creator A5085951272 @default.
• W2893103482 creator A5086765478 @default.
• W2893103482 creator A5089971063 @default.
• W2893103482 creator A5091097962 @default.
• W2893103482 date "2018-11-01" @default.
• W2893103482 modified "2023-10-12" @default.
• W2893103482 title "Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study" @default.
• W2893103482 cites W2024585092 @default.
• W2893103482 cites W2073229031 @default.
• W2893103482 cites W2096310657 @default.
• W2893103482 cites W2103414045 @default.
• W2893103482 cites W2105712999 @default.
• W2893103482 cites W2132548245 @default.
• W2893103482 cites W2137417864 @default.
• W2893103482 cites W2139311359 @default.
• W2893103482 cites W2168213451 @default.
• W2893103482 cites W2267969967 @default.
• W2893103482 cites W2519719564 @default.
• W2893103482 cites W2548551762 @default.
• W2893103482 cites W2621228814 @default.
• W2893103482 cites W2755317519 @default.
• W2893103482 cites W2761439236 @default.
• W2893103482 cites W2883284210 @default.
• W2893103482 cites W2889612530 @default.
• W2893103482 doi "https://doi.org/10.1016/s2352-3018(18)30177-2" @default.
• W2893103482 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30282603" @default.
• W2893103482 hasPublicationYear "2018" @default.
• W2893103482 type Work @default.
• W2893103482 sameAs 2893103482 @default.
• W2893103482 citedByCount "56" @default.
• W2893103482 countsByYear W28931034822018 @default.
• W2893103482 countsByYear W28931034822019 @default.
• W2893103482 countsByYear W28931034822020 @default.
• W2893103482 countsByYear W28931034822021 @default.
• W2893103482 countsByYear W28931034822022 @default.
• W2893103482 countsByYear W28931034822023 @default.
• W2893103482 crossrefType "journal-article" @default.
• W2893103482 hasAuthorship W2893103482A5001181968 @default.
• W2893103482 hasAuthorship W2893103482A5003302321 @default.
• W2893103482 hasAuthorship W2893103482A5006363203 @default.
• W2893103482 hasAuthorship W2893103482A5006929815 @default.
• W2893103482 hasAuthorship W2893103482A5009104141 @default.
• W2893103482 hasAuthorship W2893103482A5009248465 @default.
• W2893103482 hasAuthorship W2893103482A5010065694 @default.
• W2893103482 hasAuthorship W2893103482A5011644912 @default.
• W2893103482 hasAuthorship W2893103482A5017678982 @default.
• W2893103482 hasAuthorship W2893103482A5018761768 @default.
• W2893103482 hasAuthorship W2893103482A5019711611 @default.
• W2893103482 hasAuthorship W2893103482A5020544537 @default.
• W2893103482 hasAuthorship W2893103482A5021025618 @default.
• W2893103482 hasAuthorship W2893103482A5021736604 @default.

• next